Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128107 | 0.88 | F2 (0.41) | F2MAPTCTSDFDPSADRA2B | |
| SCHEMBL20112844 | 0.82 | F2 (0.39) | F2MAPTALDH1A1CTSDACHE | |
| SCHEMBL5335241 | 0.78 | KCNH3 (0.41) | F2MAPTALDH1A1 | |
| SCHEMBL2128482 | 0.78 | KDM6B (0.47) | F2MAPTALDH1A1CTSD | |
| SCHEMBL10274903 | 0.76 | MAPT (0.46) | F2MAPTALDH1A1CTSDFDPS | |
| SCHEMBL2352696 | 0.76 | NAAA (0.50) | F2MAPTALDH1A1CTSDACHE | |
| SCHEMBL20626527 | 0.76 | F2 (0.39) | F2MAPTCTSDFDPSADRA2B | |
| SCHEMBL19468970 | 0.75 | CTSD (0.44) | F2CTSDFDPSADRA2B | |
| SCHEMBL26941343 | 0.75 | ADRA2B (0.36) | F2MAPTALDH1A1ADRA2BKCNH2 | |
| SCHEMBL25383583 | 0.74 | NAAA (0.53) | MAPTALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | F2 203/4885MAPT 2191/4885ALDH1A1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.